Suzanne Iverson Hemberg becomes new CEO of CTC, while Anders Millerhovf takes a dual position as Chief Commercial Officer for CTC and CTR

Today, the Center for Translational Research (CTR) announced three major internal leadership changes within the corporate group. These changes mean that CTC:s current CEO Anders Millerhovf will take on a new dual role as Chief Commercial Officer at both CTC and CTR. Suzanne Iverson Hemberg, who is the current CEO at Toxicology Knowledge Team Sweden AB (TKT), will take over as CEO of CTC. The CEO position at TKT, in turn, will be filled by Anna Steneholm, who is a Senior Toxicology Consultant at TKT today.

“These leadership transitions mark the next step in our journey, building on a proven record of growth, trust and customer value. As demand for our expertise and specialized services continues to rise, we will expand our capabilities to deliver even greater value to customers and partners. I am proud of our internal talents and grateful for the opportunity to foster leadership through internal career development,” says Karin Meyer, the CEO of CTR.

CTC has been successfully led by CEO Anders since 2015. In his new dual role as Chief Commercial Officer for CTC and CTR he will focus on driving customer relations and business development for CTC as well as the entire corporate group under CTR. Anders, who holds an MSc in Medical Biology from Linköping University, co-founded CTC in 2011 and has thus been instrumental in leading CTC in becoming a market leader for early clinical trials in Northern Europe.

“After ten years as CEO, I feel both proud and grateful for the journey we have made together. It has been a privilege to lead CTC and to see what we have accomplished. Moving into my new role as Chief Commercial Officer gives me the opportunity to continue contributing to both CTC and CTR in new ways. I look forward to building the future together with our fantastic colleagues and clients – always true to our mission of translating science into treatment, with patients for patients,” Anders says.

Suzanne brings broad experience from both the corporate and public healthcare sectors, having previously held Senior Director positions in Laboratory Medicine at Sahlgrenska University Hospital as well as principal scientific and middle management roles at AstraZeneca. She has a PhD in Pharmacology and Toxicology from the University of Toronto after which she undertook a postdoc in Molecular Toxicology at Karolinska Institutet. Suzanne will continue her involvement in TKT as a member of the board.

“Leaving my fantastic colleagues at TKT Sweden and following Anders as CEO of CTC are both challenging endeavours. As the new CEO of CTC, I am looking forward to combining my passion for the science behind development of safe and effective therapeutics with my energy, drive and solid track record in leading in a complex environment. I am privileged to have the opportunity to lead a company that has been built with dedicated leadership,” Suzanne says.

The role changes will take effect during the last quarter of this year.